Issue 85, 2022

Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders

Abstract

The single-stranded RNA genome of SARS-CoV-2 contains some G-quadruplex-forming G-rich elements which are putative drug targets. Here, we performed a ligand-based pharmacophore virtual screening of FDA approved drugs to find candidates targeting such RNA structures. Further in silico and in vitro assays identified three drugs as emerging SARS-CoV-2 RNA G-quadruplex binders.

Graphical abstract: Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders

Supplementary files

Article information

Article type
Communication
Submitted
02 Jun 2022
Accepted
27 Sep 2022
First published
27 Sep 2022
This article is Open Access
Creative Commons BY license

Chem. Commun., 2022,58, 11913-11916

Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders

F. Moraca, S. Marzano, F. D'Amico, A. Lupia, S. Di Fonzo, E. Vertecchi, E. Salvati, A. Di Porzio, B. Catalanotti, A. Randazzo, B. Pagano and J. Amato, Chem. Commun., 2022, 58, 11913 DOI: 10.1039/D2CC03135C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements